Your browser doesn't support javascript.
How We Manage Patients With Chronic Lymphocytic Leukemia During the SARS-CoV-2 Pandemic.
Rossi, Davide; Shadman, Mazyar; Condoluci, Adalgisa; Brown, Jennifer R; Byrd, John C; Gaidano, Gianluca; Hallek, Michael; Hillmen, Peter; Mato, Anthony; Montserrat, Emili; Ghia, Paolo.
  • Rossi D; Division of Hematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.
  • Shadman M; Laboratory of Hematology, Institute of Oncology Research, Bellinzona, Switzerland.
  • Condoluci A; Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, Washington, USA.
  • Brown JR; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
  • Byrd JC; Seattle Cancer Care Alliance, Seattle, Washington, USA.
  • Gaidano G; Division of Hematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.
  • Hallek M; Chronic Lymphocytic Leukemia Center, Division of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA.
  • Hillmen P; The Ohio State University Comprehensive Cancer Center and Division of Hematology, Columbus, Ohio, USA.
  • Mato A; Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy.
  • Montserrat E; Center of Integrated Oncology Cologne Bonn and German CLL Study Group, University of Cologne, Cologne, Germany.
  • Ghia P; Haematological Malignancy Diagnostic Service, St. James's University Hospital, Leeds, United Kingdom.
Hemasphere ; 4(4): e432, 2020 Aug.
Article in English | MEDLINE | ID: covidwho-1104995
ABSTRACT
Infections are a major cause of morbidity and mortality in patients with chronic lymphocytic leukemia (CLL). These can be exacerbated by anti-leukemic treatments. In addition, the typical patients with CLL already have fragilities and background risk factors that apply to the general population for severe COVID-19. On these bases, patients with CLL may experience COVID-19 morbidity and mortality. Recurrent seasonal epidemics of SARS-CoV-2 are expected, and doctors taking care of patients with CLL must be prepared for the possibility of substantial resurgences of infection and adapt their approach to CLL management accordingly. In this Guideline Article, we aim at providing clinicians with a literature-informed expert opinion on the management of patients with CLL during SARS-CoV-2 epidemic.

Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study Language: English Journal: Hemasphere Year: 2020 Document Type: Article Affiliation country: Hs9.0000000000000432

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study Language: English Journal: Hemasphere Year: 2020 Document Type: Article Affiliation country: Hs9.0000000000000432